Safety and Efficacy of Niraparib in Metastatic Castration-resistant Prostate Cancer: Systematic Review and Meta-analysis
Notice bibliographique
Résumé
Abstract Background and Objective: In 2021, around 250,000 individuals were diagnosed with prostate cancer, making it the second leading cause of cancer-related deaths among males in the United States. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly condition, underscoring the need for novel treatments. Niraparib, a powerful and highly specific inhibitor of Poly (ADP-Ribose) Polymerase (PARP)-1 and PARP-2, is approved for use in the United States, Canada, Europe and China for certain individuals with various conditions such as ovarian, fallopian tube and primary peritoneal malignancies. Niraparib is now licensed for clinical usage in ovarian cancer at a daily dosage ranging from 200 to 300 mg. 21-23 Niraparib has shown efficacy in treating mCRPC in patients with identified DNA repair gene abnormalities. Materials and Methods: Four electronic databases – PubMed, Scopus, Cochrane Library and Web of Science were searched for relevant studies until 26 February 2024. Efficacy outcomes were radiographic progression-free survival (rPFS), time to symptomatic progression (TSP) and time to cytotoxic chemotherapy (TCC). Safety outcomes were at least one serious adverse event and treatment-emergent adverse event. The extracted data were dichotomous, and R Studio software was used for the analysis using the fixed effect model. Results: Six studies were systematically reviewed, three of which were included in the meta-analysis, involving 1298 patients. The analysis showed that niraparib is statistically significant in improving rPFS; risk ratio (RR) 1.36 (95% confidence interval [CI]: 1.22–1.52, P < 0.01), and this is consistent with the results of TSP and TCC that also revealed positive impact favouring niraparib; RR 1.11 (95% CI: 1.01–1.22, P < 0.03) and 1.14 (95% CI: 1.06–1.23, P < 0.01). However, niraparib was associated with a higher incidence rate of at least one serious adverse event and treatment-emergent adverse events; RR 1.47 (95% CI: 1.21–1.79, P < 0.01) and 1.04 (95% CI: 1.02–1.07, P < 0.01). Conclusions: Niraparib has been found to have a positive impact on rPFS, TSP and TCC, but it has also been associated with some adverse events, such as anaemia, neutropenia and thrombocytopenia. Despite the adverse events and further studies which are required to assess its safety, niraparib should be considered for clinical usage.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,007 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,000 |
| Bibliométrie | 0,002 | 0,004 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».